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Objective. To quantify the degree of plasma volume expansion that occurs during an intravenous glucose tolerance test (IVGTT).
Methods. Twenty healthy volunteers (mean age, 28 years) underwent IVGTTs in which 0.3g/kg of glucose 30% was injected as a
bolus over 1min. Twelve blood samples were collected over 75min. The plasma glucose and blood hemoglobin concentrations
were used to calculate the volume distribution (Vd) and the clearance (CL) of both the exogenous glucose and the injected ﬂuid
volume. Results. The IVGTT caused a virtually instant plasma volume expansion of 10%. The half-life of the glucose averaged
15min and the plasma volume expansion 16min. Correction of the ﬂuid kinetic model for osmotic eﬀects after injection reduced
CL for the infused volume by 85%, which illustrates the strength of osmosis in allocating ﬂuid back to the intracellular ﬂuid space.
Simulations indicated that plasma volume expansion can be reduced to 60% by increasing the injection time from 1 to 5min
and reducing the glucose load from 0.3 to 0.2g/kg. Conclusion. A regular IVGTT induced an acute plasma volume expansion that
peaked at 10% despite the fact that only 50–80mL of ﬂuid were administered.
1.Introduction
The intravenous glucose tolerance test (IVGTT) is a tool
for assessment of glucose disposal in diabetes research and
clinical investigations. The test includes a bolus injection of
hypertonic glucose and repeated measurement of the plasma
glucose and insulin concentrations over up to 3 hours,
sometimes with administration of insulin after 20min [1, 2].
Several important indices can be derived from an IVGTT,
including insulin sensitivity and beta cell function [3].
An overlooked aspect of IVGTTs is the cardiovascular
strain caused by osmotic translocation of intracellular ﬂuid
caused by hypertonic glucose. Only 50–80mL of ﬂuid are
administered, but how much and how fast the plasma
volume becomes expanded does not seem to have been
previously studied. This is of interest, as the test might be
administered to diabetic patients with limited cardiovascular
reserves.
Mathematical methods for analysis and simulation of
the disposition of hypertonic crystalloid [4, 5] and isotonic
glucose solutions [6, 7] have been developed during the past
decade. In the present study, we combine these methods to
analyzethedegreeandtimecourseofthehypervolemiceﬀect
of IVGTTs in 20 healthy volunteers.
2.SubjectsandMethods
Twenty volunteers, 8 females and 12 males, aged between
18 and 51 years (mean, 28) and with a body weight of 49–
88kg (mean, 68) were studied. The study was approved by
the Regional Ethics Committee of Stockholm, and informed
consent was obtained from the participants. Mean BMI
was 23.4 (SD 2.3) kg/m2, and the serum concentrations of
electrolytes and of HbA1c were normal in all cases. None of
the subjects used daily medication.
2.1. Procedure. The experiments were conducted at the
Department of Endocrinology at S¨ odersjukhuset and began
at approximately 8 am. After an overnight fast, each vol-
unteer was placed comfortably on a bed. In each subject,2 Computational and Mathematical Methods in Medicine
a cannula was inserted into the antecubital vein of each arm,
one for sampling blood and the other for infusing ﬂuid.
Monitoringconsistedofelectrocardiography,pulseoximetry,
and noninvasive blood pressure.
After a 30min equilibration period to obtain hemody-
namic steady state, a short regular IVGTT was performed
by administrating 0.3g/kg of glucose in a 30% solution
over 1min. Blood was sampled at 0, 2, 4, 6, 8, 10, 20,
30, 40, 50, 60, and 75min for assessment of the plasma
glucose and blood hemoglobin (Hb) concentrations. Plasma
glucose was measured by the glucose oxidase method used
by the hospital’s usual laboratory, and the Hb concentration
was measured by colorimetry (Technicon Advia, Bayer,
Tarrytown, NY, USA).
2.2. Pharmacokinetics
2.2.1. Glucose. Plasma concentration G at time t when glu-
cose was infused at rate R0 was calculated using the following
diﬀerential equation:
d(G −Gb)
dt
=
R0
Vd
−
CL
Vd
∗ (G(t) −Gb),( 1 )
where Gb is the baseline glucose, Vd is the volume of
distribution, and CLis the clearance. Since glucose enters the
cells by active transport, a decreasing amount of glucose in
Vd corresponds, in the absence of glucosuria, to the uptake
of glucose into cells [6, 7].
The half-life (T1/2) of the exogenous glucose load was
obtained as [ln2 ∗Vd/CL].
2.2.2. Fluid. Hypertonic glucose causes an osmotic shift that
draws water from the intracellular (40% of the body weight
(BW)) to the extracellular (20% of the BW) ﬂuid space.
Using the baseline serum osmolality (295mosmol/kg), the
translocated volume ft resulting from each injection was
obtained as follows [4]:
BW ∗20% ·295 +infused osmoles
BW ·20% + ft +infused volume
=
BW ·40% ·295
BW ·40% − ft
.
(2)
The kinetic model calculates the baseline volume of distribu-
tion (V) and the clearance (CL) for the sum of the injected
(R0) and translocated (ft) ﬂuid volumes. The model implies
that the ﬂuid added to the kinetic system expands V to
v, which strives to return to V by two mechanisms: ﬁrst,
elimination of ﬂuid at a rate proportional by a constant CL
to the dilution of V, and second, a baseline loss (CL0)ﬁ x e d
to 0.4mL/min to account for evaporation and basal diuresis
[4] .T h ev o l u m ec h a n g eo fv is then expressed as
dv
dt
= R0 + ft −CL0 −CL
(v − V)
V
. (3)
The dilution of v,w h i c hi sg i v e nb y( v − V)/V, was set
equal to the plasma dilution as derived from the blood
Hb concentration at baseline time 0 and at time t.H e n c e ,
[(Hb0/Hb(t)) – 1]/(1 – hematocrit0).
The optimal estimates for the unknown parameters in
the glucose and ﬂuid models were calculated for each of
the 20 experiments individually by nonlinear least-squares
regression. No weights were used. The software used was
Matlab 4.2 (Math Works Inc., Natick, Mass, USA).
The half-life (T1/2) of the infused ﬂuid volume was
obtained as [ln2 ∗ V/CL]. The result of the kinetic analysis
of glucose has been published elsewhere [8].
2.3. Statistics. The results were presented as mean and stan-
dard deviation (SD) and, when there was a skewed dis-
tribution, as the median (25th–75th percentile range). All
reported correlations were statistically signiﬁcant by P<
0.05.
3. Results
Baseline plasma glucose was 4.8 (0.5)mmol/L, and the blood
Hb concentration was 13.5 (11.7–14.0)g/dL.
All 20 experiments could be analyzed with the proposed
equations for plasma glucose and insulin kinetics. The
modeled rise in plasma glucose was 8mmol/L (Figure 1(a)),
and the plasma volume expansion, as evidenced by the
plasma dilution, was 9% at 2min (Figure 1(b)). Simulation
showed that the peak would be almost 11% at the end of the
1min injection (Figure 2(a)).
3.1. Kinetic Parameters. The Vd and CLfor the administered
glucose were 14.0 (6.5)L and 0.63 (0.26)L/min, respectively
[8].
Calculation of the osmotic ﬂuid shift resulting from
the injection of hypertonic glucose showed that each mmol
of exogenous glucose translocated 1.83mL of ﬂuid from
the intra- to the extracellular ﬂuid space. The translocated
plus injected ﬂuid volume expanded a body ﬂuid space
of 3.0 (2.5–4.0)L in size, and the CL was 0.13 (0.04–
0.44)L/min. The half-lives of the exogenous glucose and
the ﬂuid volume was similar, at 15 (12–19)min and 16 (6–
44)min, respectively. However, the variability between the
subjects was greater for the ﬂuid component (cf. Figures 1(a)
and 1(b)).
Recalculating the ﬂuid kinetics on the assumption that
1.83mL of ﬂuid was eliminated for each mmol of eliminated
glucose yielded practically the same size V but a ﬂuid
CL of only 0.02L/min (median), that is, almost all of the
disappearance of ﬂuid could be attributed to osmosis.
3.2. Simulations. Computer simulations were performed
based on the average parameters obtained by the kinetic
analysis of the glucose and ﬂuid kinetics.
The simulations suggested that the brisk peak in plasma
dilution at the end of the injection of hypertonic glucose
could be reduced to 60% by lowering the dose of glucose
from 0.3 to 0.2g/kg and extending the time of injection from
1t o5m i n( F i g u r e2(a)).
Modiﬁcation of the IVGTT could also be justiﬁed in
clinical situations associated with altered glucose kinetics.Computational and Mathematical Methods in Medicine 3
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Figure 1: (a) Change in plasma glucose concentration. (b) Dilution of venous plasma calculated from changes in the blood hemoglobin
concentration in response to an intravenous injection of 0.3g/kg of glucose over 1min. Each experiment is represented by a thin line and
the modeled average by a thick line.
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Figure 2: (a) Simulation showing the plasma volume expansion that would ensue if the injection time was increased to 5min (left) from
1min (right) for an IVGTT dose of 0.2g/kg and 0.3g/kg of glucose, respectively. (b) Simulation of the plasma glucose level if the glucose
load was decreased to 0.2g/kg (left) from 0.3g/kg (right) in surgical patients (solid line) and in volunteers (broken line). The kinetic data for
volunteers were taken from the present study, and those for surgery (Vd = 9.1L and CL = 0.21L/min) were derived from [7].
Simulations using Vd = 9.1L and CL = 0.21L/min as
derived from a previous study of laparoscopic cholecystec-
tomy [7] indicated that the conventional dose for an IVGTT
of0.3g/kg would,inthisclinicalsetting, raiseplasma glucose
to>12mmol/Lduringaslongatimeas30min,duringwhich
glucosuria could ensue. In contrast, the lower dose, 0.2g/kg,
would exceed this limit only during 10min (Figure 2(b)).
4. Discussion
The hypertonic glucose caused a virtually instant plasma
volume expansion of 10%, which corresponded to approxi-
mately 300mL in our volunteers. Most of this volume (75%)
was allocated from the intracellular ﬂuid space by virtue of
osmosis.Thereturnoftheplasmavolumetonormalwasalso
governed by osmosis, as CL for the ﬂuid became almost nil
when the kinetic model was corrected for the redistribution
of water driven by the uptake of glucose to the cells.
Volume expansion was much greater than would be
expected if assuming that ﬂuid translocated by osmosis
is distributed throughout the extracellular ﬂuid space. If
that had been the case, the plasma volume expansion
of 10% would have represented an extracellular volume
expansionofalmost1.4L,whichisunreasonableconsidering
the limited amount of injected osmotically active glucose
molecules. Rather, mass balance calculations indicate that4 Computational and Mathematical Methods in Medicine
the translocated plus injected ﬂuid volume was in the range
of 300mL. Hence, the size of the body ﬂuid space expanded
by the infused volume could not have been larger than
the plasma volume. This ﬁnding is not intuitive but is in
agreementwithpreviouskineticstudiesbasedonIVinfusion
of isotonic glucose solutions in healthy volunteers [6, 9]a n d
in surgical [7] and diabetic [10] patients.
Plasma dilution of 10% is not completely trivial, as it
corresponds to that measured at the end of a 45min infusion
of 12.5mL/kg (approximately 1L) of glucose 2.5% with
electrolytes [9]. Moreover, plasma volume expansion during
an IVGTT develops so quickly that the circulatory system
cannot adapt gradually to the situation. In our study, the
r a p i do n s e te v e nm a d ei td i ﬃcult to capture the peak. As
Hb was sampled 1min after the end of the injection, the
curve in Figure 1(b) indicated a plasma dilution of only
9%. On the other hand, the computer simulation shown in
Figure 2(a) indicates that the maximum dilution at the very
end of the injection would be even somewhat higher than
10% (Figure 2(a)). However, this value is theoretical, as the
circulation time is approximately 1min.
The degree and speed of the onset of plasma volume
expansion would be far less dramatic by decreasing the dose
of hypertonic glucose from 0.3 to 0.2g/kg and by increasing
theinjectionfrom1-2minutesto5minutes.Thesimulations
we performed based on the kinetic parameters suggest that
the plasma volume expansion would then be cut in half and
also develop more slowly.
The kinetic analyses also argue against the use of a
conventional IVGTT in the presence of surgery. A smaller
dose, 0.2g/kg, would smooth the hyperglycemia enough to
prevent prolonged glycosuria (≈30min) in this setting. The
kinetics for the doses of glucose simulated here are known to
be linear; that is, the same values of Vd and CL are obtained
when the dose and infusion time are changed [6].
A limitation of the present study is that no invasive
hemodynamic monitoring was performed. However, one
would hardly expect problems in the cardiovascular adap-
tation to the rapid onset of plasma volume expansion
in the group of healthy volunteers used in this study.
Hemodynamic measurements would be of greater interest in
elderly subjects with reduced cardiovascular reserves, such
as diabetic patients. Insulin-resistant persons, such as those
with obesity, would also be likely to experience a more long-
lasting plasma volume expansion with an ensuing risk of
hemodynamic stress. The reason is that the ﬂuid clearance is
governed almost completely by the rate of uptake of glucose
to the cells, which occurs more slowly in insulin-resistant
states.
In conclusion, the plasma volume expansion resulting
from an IVGTT is greater than commonly believed (10%)
because the injected and osmotically translocated ﬂuid have
a volume of distribution that corresponds only to the plasma
volume instead of to the entire extracellular ﬂuid space. A
smaller dose and slower injection time might be appropriate
if an IVGTT is applied in debilitated or surgical patients.
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